CompaniesBioNumerik Pharmaceuticals

BioNumerik Pharmaceuticals

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (7)
View all

Total Trials

7

As Lead Sponsor

6

As Collaborator

1

Total Enrollment

1,973

By Phase

PHASE3: 3PHASE1/PHASE2: 1PHASE1: 1PHASE2: 2

By Status

COMPLETED: 6TERMINATED: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
NCT00039780
NCT00062478
NCT00097903
NCT00477282
Hover over trial bars to see details

Recent Trials

NCT00966914Lead Sponsor
Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin
PHASE3Completed
540 participants
Started: Apr 30, 2010 · Completed: Jun 30, 2013
NCT00477282Lead Sponsor
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
PHASE3Completed
509 participants
Started: Aug 31, 2007 · Completed: Jun 30, 2013
NCT00358319Collaborator
Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma
PHASE1/PHASE2Terminated
42 participants
Started: Mar 31, 2005 · Completed: Apr 30, 2007
NCT00097903Lead Sponsor
Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer
PHASE1Completed
32 participants
Started: May 31, 2004 · Completed: May 31, 2013
NCT00062491Lead Sponsor
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
PHASE2Completed
46 participants
Started: May 31, 2002 · Completed: Nov 30, 2005
View all 7 trials →
Funding History (7)
D
Nov 8, 2012
Filing
D
Nov 12, 2010
Filing
S-1/A
Mar 22, 2005
Filing
S-1/A
Oct 14, 2004
Filing
S-1/A
Aug 24, 2004
Filing
S-1
Jun 8, 2004
Filing
S-1
Mar 2, 2001
Filing